Rivian (RIVN) stock surged on Friday morning after the EV-maker reported strong delivery guidance for the year, as it ramps up for the release of its R2 vehicle which the company said is on track for ...

After a brutal year for the US electric-vehicle industry, Rivian Automotive Inc. handed investors a rare reason for optimism. The EV manufacturer reported better-than-expected fourth-quarter results ...

Rivian has unveiled a prototype of its new electric SUV, the R2, which is expected to start around $45,000. The five-seat vehicle is slated for release in the first half of 2026 and will have an ...

Rivian CEO RJ Scaringe posits that the success of the Tesla Model Y represents a huge opportunity for the 2026 Rivian R2. He argues that the current crop of electric compact SUVs all follow the Model ...

CEO Robert Scaringe highlighted that "2025 was a year focused on execution at Rivian as we laid the foundations for scaling our business" and underscored the R1S's market position, stating it was "the ...

Rivian's share price has plunged about 85% since going public in 2021. Now, the EV maker is betting its future on a new vehicle: Rivian R2, a $45,000 midsize SUV. Founder and CEO, RJ Scaringe, gives ...

The 2026 Rivian R2, priced at roughly half the cost of an R1, is the brand’s make-or-break vehicle. Can a 300-plus-mile electric SUV pared down to meet an aggressive $45,000-ish opening price still ...

There is significant anticipation for Rivian’s latest launch, and the brand is keen to further promote it by leveraging an iconic pop culture theme. Marketing is crucial for product differentiation, ...

After a string of high-profile crashes in the US and overseas, automakers are facing increased scrutiny over something as basic as door handle design. Once a simple mechanical feature, door handles ...

South Africans now need at least R2 846 per person per month to cover basic food and non-food needs, according to the latest national poverty lines released by Statistics South Africa, reflecting the ...

Leah Z. Rand ([email protected]) is a postdoctoral fellow in the Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham ...